AbbVie Inc
USUSDAbbVie Inc (XETRA:4AB) — Biotechnology: Pharmaceutical Preparations. Número de bolsas en las que cotizan las acciones de la empresa: 4. En esta página: cotización y gráfico, dividendos, principales accionistas e historial del número de acciones.
Sobre la Empresa
- Sitio Web
- abbvie.com
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Central
- North Chicago, United States
- Consejero Delegado
- Robert A. Michael
- Empleados
- 57 000
- Fundada
- 2012
- Cotiza Desde
- 17.05.2016 (XETRA:4AB)
- Acciones en Circulación
- Capital Flotante
- 1.76 mil M
- Capitalización Bursátil
- 470.55 mil M USD
- Insiders
- 0.11%
- Inversores Institucionales
- 77.37%
- Industria (SIC)
- Pharmaceutical Preparations
- Forma Jurídica
- XTIQ
- ISIN
- US00287Y1091
- LEI
- FR5LCKFTG8054YNNRU85
- P/E
- 80.6
- Ratio de Reparto
- 190%
- FCF
- 18.2 mil M USD
- Pagos / FCF
- 66%
- Deuda
- 70.8 mil M USD3.5 a. de FCF
- Racha de Dividendos
- 13 a.
- Beneficios, FCF y dividendos pagados — para los 12 meses hasta 30.06.2026 (el último informe de la compañía).
Descripción
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Bolsas y Tickers
Dividendos
AbbVie Inc (4AB) paga dividendos trimestralmente. Por año (12 meses hasta e incluyendo el último pago anunciado): 6.007 EUR por acción (pagos: 4). Eso representa aproximadamente el 2.44% del precio actual de la acción. Según el historial de pagos, se espera la próxima fecha ex-dividendo alrededor de 13.01.2027. Historial de dividendos ininterrumpido: 13 años.
| Fecha Ex | Pago | Importe | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-07-15 | — | 1.5215 EUR | 0.7/2.8 % | trimestral | XETRA:4AB |
| 2026-04-15 | — | 1.5215 EUR | 0.9/3.4 % | trimestral | XETRA:4AB |
| 2026-01-16 | — | 1.5215 EUR | 0.8/3.1 % | trimestral | XETRA:4AB |
| 2025-10-15 | — | 1.4424 EUR | 0.7/2.9 % | trimestral | XETRA:4AB |
| 2025-07-15 | — | 1.4424 EUR | 0.9/3.5 % | trimestral | XETRA:4AB |
| 2025-04-15 | — | 1.4424 EUR | 0.9/3.6 % | trimestral | XETRA:4AB |
| 2025-01-15 | — | 1.4424 EUR | 0.8/3.3 % | trimestral | XETRA:4AB |
| 2024-10-15 | — | 1.3632 EUR | 0.8/3.0 % | trimestral | XETRA:4AB |
| 2024-07-15 | — | 1.3632 EUR | 0.9/3.4 % | trimestral | XETRA:4AB |
| 2024-04-12 | — | 1.3632 EUR | 0.9/3.4 % | trimestral | XETRA:4AB |
| 2024-01-12 | — | 1.3632 EUR | 0.9/3.5 % | trimestral | XETRA:4AB |
| 2023-10-12 | — | 1.3017 EUR | 0.9/3.7 % | trimestral | XETRA:4AB |
| 2023-07-13 | — | 1.3017 EUR | 1.1/4.2 % | trimestral | XETRA:4AB |
| 2023-04-13 | — | 1.3017 EUR | 0.9/3.4 % | trimestral | XETRA:4AB |
| 2023-01-12 | — | 1.3017 EUR | 0.9/3.5 % | trimestral | XETRA:4AB |
| 2022-10-13 | — | 1.2401 EUR | 0.9/3.4 % | trimestral | XETRA:4AB |
| 2022-07-14 | — | 1.2401 EUR | 0.8/3.2 % | trimestral | XETRA:4AB |
| 2022-04-13 | — | 1.2401 EUR | 0.8/2.3 % | trimestral | XETRA:4AB |
| 2022-01-13 | — | 1.2401 EUR | 1.0/2.0 % | trimestral | XETRA:4AB |
| 2021-10-14 | — | 1.1434 EUR | 1.2/1.2 % | trimestral | XETRA:4AB |
Noticias de Esta Semana
Comunicados de prensa desde la página web para inversores de la empresa, actualizados diariamente. Los enlaces conducen a la página web de la empresa. Los titulares están en el idioma original, como en la página web de la empresa.
Principales Accionistas
| Titular | Participación | Acciones | Fecha del Informe |
|---|---|---|---|
| BlackRock | 8.46% | 149.49 M | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 115.4 M | 2026-06-30 |
| State Street Corporation | 4.67% | 82.6 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 56.09 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.74% | 48.48 M | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.71% | 47.86 M | 2026-06-30 |
| Geode Capital Management… | 2.66% | 47 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 45.78 M | 2026-06-30 |
| Morgan Stanley | 2.2% | 38.9 M | 2026-06-30 |
| Capital Research Global… | 1.7% | 30.1 M | 2026-06-30 |
| NORGES BANK | 1.45% | 25.55 M | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 23.84 M | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 22.85 M | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 21.61 M | 2026-08-31 |
| Bank of America Corporat… | 1.2% | 21.24 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 16.82 M | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.7 M | 2026-08-31 |
| AMERICAN MUTUAL FUND | 0.63% | 11.15 M | 2026-07-31 |
| Capital Income Builder | 0.57% | 10.06 M | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 10 M | 2026-07-31 |
| GONZALEZ RICHARD A (Dire… | ≈0.02% | 386 479 | 2025-03-31 |
| SALEKI-GERHARDT AZITA (C… | ≈0.01% | 220 682 | 2026-02-18 |
| MICHAEL ROBERT A. (Chief… | ≈0.01% | 215 260 | 2026-02-18 |
| FREYMAN THOMAS C (Direct… | ≈0.01% | 135 751 | 2026-05-08 |
| STEWART JEFFREY RYAN (Of… | ≈0.01% | 108 321 | 2026-02-18 |
| DONOGHOE NICHOLAS (Offic… | ≈0% | 74 430 | 2026-08-14 |
| REENTS SCOTT T. (Chief F… | ≈0% | 60 415 | 2026-02-18 |
| THAKKAR ROOPAL (Officer) | ≈0% | 60 413 | 2026-02-18 |
| TILTON GLENN FLETCHER (D… | ≈0% | 51 914 | 2025-05-09 |
| RAPP EDWARD J (Director) | ≈0% | 45 964 | 2026-05-08 |
| The Vanguard Group | — | — | — |
